LBG
REGN icon

Lloyds Banking Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Lloyds Banking Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,131
Closed -$407K – 336
2014
Q3 		$407K Sell
1,131
-673
-37% -$226K 0.11% 199
2014
Q2 		$509K Sell
1,804
-18,928
-91% -$5.61M 0.12% 186
2014
Q1 		$6.22M Sell
20,732
-499
-2% -$154K 0.06% 270
2013
Q4 		$5.84M Buy
21,231
+2,860
+16% +$823K 0.05% 275
2013
Q3 		$5.75M Sell
18,371
-261
-1% -$68.7K 0.06% 241
2013
Q2 		$4.19M Buy
+18,632
New +$4.34M 0.04% 278

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Lloyds Banking Group's REGN Position: Q4 2014 in Review

Lloyds Banking Group sold out of Regeneron Pharmaceuticals (REGN) in Q4 2014, closing a stake of 1,131 shares — an estimated $407K sold.

Lloyds Banking Group first reported a position in REGN in Q2 2013 and held it in 6 quarters. The position peaked at $6.22M in Q1 2014. 512 funds tracked by Wall St. Rank hold REGN as of Q4 2014.

  • Lloyds Banking Group reported no remaining Regeneron Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Lloyds Banking Group sold 1,131 Regeneron Pharmaceuticals shares in Q4 2014, an estimated $407K.
  • Lloyds Banking Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • Lloyds Banking Group's Regeneron Pharmaceuticals position peaked at $6.22M in Q1 2014.
  • 512 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2014.

Based on Lloyds Banking Group's 13F filing for Q4 2014, filed 12 Feb 2015.